Thromboembolic complications in cancer

częstym powikłaniem choroby nowotworowej. Wiele objawów stanu zakrzepowego w tych chorobach uwidacznia się zarówno w patologicznych wynikach układu krzepnięcia, jak i w masywnych zatorach mogących doprowadzić do śmierci pacjenta. Głęboka zakrzepica żylna w nodze i zatorowość płucna są dwoma najczęstszymi powikłaniami zakrzepowo-zatorowymi osób chorych na nowotwory. Prokoagulanty, takie jak czynnik tkankowy (ang. tissue factor –TF), znajdują ekspresję na wielu komórkach nowotworowych; obrót metaboliczny i aktywność płytek krwi są również zwiększone. Uszkodzony śródbłonek i zaburzony przepływ krwi także mogą odgrywać rolę w przebiegu procesu nowotworowego. Poznanie mechanizmu nadkrzepliwości związanego z nowotworami może pomóc w zidentyfikowaniu bardziej celowanych terapii, aby przeciwdziałać incydentom zakrzepowo-zatorowym u pacjentów chorych na nowotwory, zwłaszcza gdy stosowane jest leczenie operacyjne lub chemioterapeutyczne.

[1]  C. Klersy,et al.  Ovarian cancer and venous thromboembolic risk. , 2005, Gynecologic oncology.

[2]  X. Wang,et al.  Venous thromboembolism syndrome in gynecological cancer , 2005, International Journal of Gynecologic Cancer.

[3]  Brian J. Smith,et al.  Thromboembolic events in patients treated with definitive chemotherapy and radiation therapy for invasive cervical cancer. , 2005, Gynecologic oncology.

[4]  Giancarlo Agnelli,et al.  Antithrombotic therapy for venous thromboembolic disease: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. , 2004, Chest.

[5]  L. Deangelis,et al.  Stroke in patients with cancer , 2004, Neurology.

[6]  G. Lip,et al.  The hypercoagulable state of malignancy: pathogenesis and current debate. , 2002, Neoplasia.

[7]  M. Monreal,et al.  Thrombotic Complications of Central Venous Catheters in Cancer Patients , 2001, Acta Haematologica.

[8]  C. Catena,et al.  Abnormalities of coagulation in hypertensive patients with reduced creatinine clearance. , 2000, The American journal of medicine.

[9]  R J Hettiarachchi,et al.  Undiagnosed malignancy in patients with deep vein thrombosis , 1998, Cancer.

[10]  G. Hommel,et al.  Blood rheology during chemotherapy in patients with ovarian cancer. , 1998, Thrombosis research.

[11]  P. Prandoni.  Antithrombotic Strategies in Patients with Cancer , 1997, Thrombosis and Haemostasis.

[12]  M. Levine,et al.  Prevention of Thrombotic Disorders in Cancer Patients Undergoing Chemotherapy , 1997, Thrombosis and Haemostasis.

[13]  M. Prins,et al.  Newly Diagnosed Malignancy in Patients with VenousThromboembolism. Search or Wait and See? , 1997, Thrombosis and Haemostasis.

[14]  A. Gadducci,et al.  Preoperative D-dimer plasma assay is not a predictor of clinical outcome for patients with advanced ovarian cancer. , 1997, Gynecologic oncology.

[15]  A. Gadducci,et al.  Prothrombin fragment F1+2 and thrombin-antithrombin III complex (TAT) plasma levels in patients with gynecological cancer. , 1996, Gynecologic oncology.

[16]  R. Silverstein,et al.  Hypercoagulability in cancer. , 1996, Hematology/oncology clinics of North America.

[17]  A. Gadducci,et al.  Preoperative evaluation of D-dimer and CA 125 levels in differentiating benign from malignant ovarian masses. , 1996, Gynecologic oncology.

[18]  T. Kitazono,et al.  Multiple Brain Infarction and Hemorrhage by Nonbacterial Thrombotic Endocarditis in Occult Lung Cancer— , 1994, Angiology.

[19]  M. Hamada,et al.  Cerebral and myocardial infarction induced by nonbacterial thrombotic endocarditis in a patient with ovarian cancer: report of a case. , 1988, Japanese journal of medicine.

[20]  S. Matsushita,et al.  Nonbacterial thrombotic endocarditis as a cause of cerebral and myocardial infarction. , 1984, Japanese circulation journal.

[21]  J. Willoughby,et al.  Non-bacterial thrombotic endocarditis in early cancer. , 1976, British medical journal.

[22]  R. Dodge,et al.  Venous thromboembolism prophylaxis: patients at high risk to fail intermittent pneumatic compression. , 2003 .

[23]  G. Lip,et al.  Cancer and the prothrombotic state. , 2002, The Lancet. Oncology.

[24]  L. Gordon,et al.  Thrombotic Microangiopathy Manifesting as Thrombotic Thrombocytopenic Purpura/Hemolytic Uremic Syndrome in the Cancer Patient , 1999, Seminars in thrombosis and hemostasis.

[25]  M. Levine,et al.  The Thrombophilic State Induced by Therapeutic Agents in the Cancer Patient , 1999, Seminars in thrombosis and hemostasis.

[26]  J. Stoot,et al.  Thrombin-antithrombin III and D-dimer plasma levels in patients with benign or malignant ovarian tumours. , 1998, Scandinavian journal of clinical and laboratory investigation.

[27]  M. Johnson.  Bleeding, clotting and cancer. , 1997, Clinical oncology (Royal College of Radiologists (Great Britain)).

[28]  荻野 英夫.  Association of thrombosis-inducing activity (TIA) with fatal hypercoagulable complications in patients with lung cancer , 1995 .